According to FutureWise analysis the Chordoma Disease Market in 2025 is US$ 4.71 billion, and is expected to reach US$ 14.39 billion by 2033 at a CAGR of 14.98%. The rise in chordoma cases is largely due to increased awareness and earlier diagnoses of rare cancers. Advances in molecular biology and targeted therapies, along with emerging treatments like immunotherapy and precision medicine, offer new hope for patients. Additionally, rising investments in rare disease research and clinical trials are expected to accelerate market development.
Chordoma is a rare and slowly growing malignant tumor that originates from remnants of the embryonic notochord found along the axial skeleton. This tumor has an annual incidence of approximately 1 case per million people, translating to around 300 new cases in the United States each year. It accounts for less than 1% of all primary bone tumors and 1–4% of malignant bone neoplasms. Chordomas primarily affect adults, with a peak incidence occurring between the ages of 50 and 60, and they show a male predominance of about 2:1. These tumors can be classified based on their location: sacrococcygeal (50% of cases), spheno-occipital (35%), and mobile spine (15%). Pediatric cases, which constitute less than 5% of all chordomas, are generally found in the cranial region and tend to be more aggressive.
Histological examination of chordomas reveals unique physaliphorous (bubble-bearing) cells that contain vacuolated cytoplasm within a myxoid matrix. These tumors typically stain positive for certain markers including brachyury (T gene, located at 6q27), cytokeratins, S100, and epithelial membrane antigen (EMA). The duplication of the T gene is a key characteristic that helps differentiate chordomas from similar tumors like chondrosarcomas. Chordomas can be further categorized into subtypes: conventional (the most common), chondroid (which has a hyaline matrix and a better prognosis), and dedifferentiated (high-grade with poor survival rates, making up less than 5%).
Clinically, chordomas manifest through symptoms caused by mass effect. Sacral tumors can lead to bowel and bladder dysfunction or sciatica, while clival tumors may result in cranial neuropathies, including diplopia and dysphagia, or issues related to pituitary function. Imaging studies, particularly MRI, typically show T2-hyperintense, lobulated midline masses accompanied by bone destruction and soft-tissue extension. A definitive diagnosis is made through biopsy, with confirmation of the tumor's origin achieved through brachyury immunohistochemistry.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Chordoma Disease Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Chordoma Disease Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.